Advertisement

Topics

Shire Receives Approval of FIRAZYR (icatibant injection) for the Treatment of Hereditary Angioedema (HAE) Attacks in Japan

11:58 EDT 21 Sep 2018 | Investing News Network

Shire (LSE:SHP,NASDAQ:SHPG) the leading global biotechnology company focused on rare diseases, announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted manufacturing and marketing authorisation for FIRAZYR (icatibant injection), for the acute treatment of hereditary angioedema (HAE) attacks in adult patients with HAE. As quoted in the press release: HAE is a … Continued

The post Shire Receives Approval of FIRAZYR (icatibant injection) for the Treatment of Hereditary Angioedema (HAE) Attacks in Japan appeared first on Investing News Network.

Original Article: Shire Receives Approval of FIRAZYR (icatibant injection) for the Treatment of Hereditary Angioedema (HAE) Attacks in Japan

NEXT ARTICLE

More From BioPortfolio on "Shire Receives Approval of FIRAZYR (icatibant injection) for the Treatment of Hereditary Angioedema (HAE) Attacks in Japan"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...